Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers. A prostate cancer diagnosis does not have to…
Many patients with skin cancer who were treated with immune checkpoint inhibition experienced long-term side effects, although some resolved over time, research showed. Chronic immune-related side effects were common in patients with skin cancer who were treated with postsurgical Opdivo…
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins. Morana Vojnic of Rutgers Cancer Institute and RWJBarnabas Health answers common questions about navigating a brain cancer diagnosis and…
In a phase 3 trial, the Breast Cancer Locator was noninferior to wire localization and lowered positive margin rates in nonpalpable breast cancer. In a prespecified sensitivity analysis stratified by final tumor type on pathology, the TD was –7.5% (95.4% CI, –14.7% to –0.3%), and the…
Bispecific antibodies targeting PD-L1 showed activity across first-, second-, and later-line advanced neuroendocrine carcinoma in 3 trials presented at ESMO 2026. At the 2026 European Society for Medical Oncology (ESMO) Congress, investigators presented results from 3 trials evaluating bispecific antibodies that pair PD-L1 blockade…
Experts at the 2025 ICE-T Symposium reviewed CAR T-cell therapy, bispecific antibodies, and gene therapy across myeloma, lymphoma, autoimmune disease, and solid tumors, emphasizing safety and access. The analysis included 128 patients treated with BCMA-directed CAR T-cell therapy between December 2019 and December…
The use of a 31-gene genetic expression profile helps to identify patients with melanoma at low risk of progression following surgery, resulting in fewer follow-up clinic visits, according to research published in JAMA Surgery. The National Comprehensive Cancer Network (NCCN)…
Ronald Chin reflects on hospitality, setting boundaries and accepting his body, and how his greatest strengths and struggles both come from one open heart. I am endlessly curious about people, ideas and the deeper meaning behind life. I find great…
A clinical trial will test zanubrutinib plus sonrotoclax as a fixed-duration, chemotherapy-free treatment for hairy cell leukemia, aiming for undetectable disease. Francesco Forconi: I am a Professor of Hematology at the University of Southampton, practicing at Southampton General Hospital. I…
Faustine Nouvel, of the Department of Medical Oncology at Gustave Roussy, presented the findings in a poster at the 2026 European Society for Medical Oncology (ESMO) Congress. Overall, the median OS from diagnosis in the FGFR-altered population was 38.4 months (95% CI, 32.4-55.3). From…
Oncology news from OncoDaily, CancerNetwork, OncLive, Targeted Oncology, the ASCO Post and CURE: trial results, approvals and cancer care.
An article joins this feed when it matches these terms. Each one is also a search of its own.